Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on exciting news coming out of ASH multiple myeloma patients

Published: 14 December 2016

Recent Videos: Multiple Myeloma

video

Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM

Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes what physicians should be aware of when ...

video

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, considers whether combining pembrolizumab and lenalidomide is effective when managing multiple ...

video

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on the effectiveness of CAR T-cell therapy in treating multiple ...

video

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on whether pomalidomide can be an effective salvage therapy for ...

video

Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients

Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, discusses the data presented at ASCO 2017 regarding ...

video

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes how immunotherapies are being integrated into multiple ...

video

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, explains how she expects personalized medicine to impact ...

video

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, comments on how ...

video

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, provides feedback on ...

video

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, outlines the most ...

Related Videos

video-image

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

video-image

Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients

video-image

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today